According to WiseGuy Reports, the Injectable Sealants Market Size was valued at USD 5.15 billion in 2024 and increased to USD 5.42 billion in 2025. The market is projected to reach USD 9 billion by 2035, registering a CAGR of 5.2% during the forecast period from 2026 to 2035. Rising demand for minimally invasive procedures, increasing surgical volumes, growing wound care requirements, an aging population, and advancements in medical sealant technologies are supporting market expansion. Major companies profiled include Baxter International, Medtronic, W. L. Gore & Associates, AptarGroup, AdvaCare, MediWound, Cardinal Health, Becton Dickinson, Abbott Laboratories, Terumo Corporation, Stryker Corporation, Smith & Nephew, B. Braun Melsungen, and Johnson & Johnson.
Market Overview
Injectable sealants are increasingly being incorporated into medical procedures where controlled tissue adhesion, wound closure, bleeding management, and bonding of biological structures are required. These products can provide clinicians with additional options for managing wounds and surgical sites while supporting procedural efficiency.
The market encompasses biologics, synthetic polymers, and adhesive-based formulations. Products are available in liquid, gel, and paste forms, allowing manufacturers to address different clinical requirements. Applications include tissue adhesion, wound closure, bone adhesion, and dental procedures.
Hospitals remain a major end-use environment, while clinics and ambulatory surgical centers contribute to demand as healthcare systems increasingly adopt outpatient and minimally invasive treatment models.
Market Size Reached in 2025
The market reached USD 5.42 billion in 2025, compared with USD 5.15 billion in 2024. The increase reflects continued demand for surgical products that can support wound management and tissue repair.
Growing surgical activity is an important contributor to market development. As the number of procedures increases across general surgery, orthopedics, dentistry, and other specialties, demand for specialized closure and adhesion technologies is also expanding.
The adoption of injectable formulations can provide healthcare professionals with application flexibility, particularly where conventional suturing or mechanical closure may not be suitable as the only approach.
Expected Market Size by 2035
The market is forecast to reach USD 9 billion by 2035. Continued development of healthcare infrastructure and increasing access to surgical treatment are expected to broaden the addressable market.
Orthopedic procedures represent an important opportunity, particularly for applications involving bone adhesion and tissue management. Expanding wound care requirements can also support adoption as healthcare providers seek efficient approaches for treating surgical and traumatic wounds.
Emerging markets may provide additional growth potential as healthcare infrastructure improves and advanced medical technologies become more accessible.
Market CAGR
The market is expected to register a CAGR of 5.2% between 2026 and 2035. This steady growth is supported by increasing procedure volumes, technological development, and broader adoption of advanced sealant solutions.
Product innovation is likely to remain central to market development. Manufacturers are working toward formulations that provide reliable adhesion, ease of application, appropriate handling characteristics, and compatibility with different clinical environments.
Key Growth Drivers
The growing preference for minimally invasive procedures is a significant market driver. Injectable sealants can complement minimally invasive techniques by providing localized tissue adhesion and wound-management capabilities.
Increasing surgical volumes worldwide are another major factor. Greater demand for orthopedic, dental, general, and other surgical procedures creates opportunities for sealant manufacturers.
The aging population also contributes to long-term demand. Older populations often require greater access to surgical and wound-care services, supporting consumption of products used during tissue repair and procedural management.
Healthcare infrastructure development is further expanding access to advanced medical products, particularly across emerging markets.
Emerging Market Trends
Advancements in formulation technology are influencing product development. Manufacturers are exploring biologic and synthetic materials with improved handling, adhesion, and application characteristics.
Gel and paste formulations can provide alternatives for procedures requiring different levels of control and coverage. Liquid formulations may be suitable for applications requiring rapid distribution across targeted areas.
The increasing use of ambulatory surgical centers is another important trend. As healthcare systems seek to manage procedures efficiently outside traditional inpatient settings, demand for convenient surgical-support products can increase.
Personalized and procedure-specific solutions are also emerging as manufacturers seek to address the requirements of different specialties.
Competitive Landscape
The competitive environment includes global medical-device companies, pharmaceutical organizations, specialty wound-care businesses, and healthcare product manufacturers. Companies compete through product performance, formulation innovation, clinical applications, distribution capabilities, and geographic expansion.
Baxter International, Medtronic, W. L. Gore & Associates, AptarGroup, AdvaCare, MediWound, Cardinal Health, Becton Dickinson, Abbott Laboratories, Terumo Corporation, Stryker Corporation, Smith & Nephew, B. Braun Melsungen, Sealed Air Corporation, and Johnson & Johnson are among the companies profiled.
Market participants are expected to continue investing in advanced formulations, minimally invasive applications, wound-care technologies, orthopedic solutions, and expansion into emerging healthcare markets.
